1 / 7

Strengths and Weaknesses of TB Drug Management Democratic Republic of Congo, Congo Brazzaville, Uganda, Nigeria, and Ben

Strengths and Weaknesses of TB Drug Management Democratic Republic of Congo, Congo Brazzaville, Uganda, Nigeria, and Benin. Group 1 Countries. Uganda Democratic Republic of Congo Congo Brazzaville Nigeria Benin Republic. Policy and Legal Framework: Strengths.

KeelyKia
Télécharger la présentation

Strengths and Weaknesses of TB Drug Management Democratic Republic of Congo, Congo Brazzaville, Uganda, Nigeria, and Ben

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Strengths and Weaknesses of TB Drug Management Democratic Republic of Congo, Congo Brazzaville, Uganda, Nigeria, and Benin

  2. Group 1 Countries • Uganda • Democratic Republic of Congo • Congo Brazzaville • Nigeria • Benin Republic

  3. Policy and Legal Framework: Strengths • NDP is present in all countries. In Congo Brazzaville, it is developed but not implemented. • Most countries have TB drugs on the EDL (except DRC). • Special consideration for donated drugs; all require evidence of quality control (+, -).

  4. Policy and Legal Framework: Weaknesses • Weak enforcement of policies, also in the private sector • Labs for QC not adequate • DOTS not widespread (except Benin) • Government funding levels inadequate (except Benin)

  5. Selection Process • All countries have protocols (STGs), however each country’s STGs may differ • Weakness: Forms and dosages differ within country • Regimen changes have been successful • Weakness: Problems with wastage

  6. Distribution and Use • All NTP involved in quantification • Weakness: Data questionable (except Benin, CB) • Drug management information systems are sometimes weak • Movement of drugs from the central to the regional level works well • Weakness: Movement from the regional to peripheral level is a problem

  7. Distribution and Use, continued • Use of blister packs has improved compliance and reduced wastage (Nigeria, Uganda)

More Related